The landscape of diabetes care is evolving with the emergence of skin-applied GLP-1 therapy. These convenient delivery systems offer a potentially less invasive alternative to needle administrations for individuals dealing with diabetes 2. They deliver a GLP-1 agonist directly through the epidermis, circumventing the need for daily injections and p